Genetic testing company Natera (NASDAQ: NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696.6 million. Its GAAP loss of $0.60 per share was 8.4% below analysts’ consensus estimates.

Is now the time to buy NTRA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-anticipated GAAP loss. Management attributed the revenue momentum primarily to strong adoption in women’s health and oncology, with CEO Steven Leonard Chapman highlighting the rapid scale-up of the new Fetal Focus product and record growth in clinical oncology testing. The company noted that exceptional volume growth, especially in the closing weeks of the quarter, led to a temporary margin impact as more samples remained in process at quarter end, affecting cost recognition.

Looking ahead, management’s guidance is shaped by continued confidence in core volume expansion, new product launches, and rising average selling prices, particularly for the Signatera oncology test. Chapman emphasized the upcoming launch in Japan and progress on the FIND early cancer detection study as key growth opportunities, while CFO Michael Brophy noted that further improvements in gross margin and operating scale are expected as transient costs normalize. The company is also increasing investment in clinical trials and product innovation, with Brophy stating, “We are well positioned to drive more efficiency and maintain our leadership position across the portfolio.”

Key Insights from Management’s Remarks

Management attributed first quarter performance to significant new product launches, strong clinical data, and ongoing expansion in both core U.S. and international markets.

• Fetal Focus launch momentum: The recent introduction of Fetal Focus, a next-generation non-invasive prenatal test (NIPT), drove rapid adoption among clinicians, with the product nearing a 200,000 annualized run rate based on strong data from the multi-site EXPAND trial.
• Oncology segment acceleration: Clinical oncology testing volumes grew 55% year-over-year, driven by record demand for Signatera and increased physician adoption across core cancer types like colorectal and breast, as well as new contributions from lymphoma.
• Signatera pricing tailwinds: Average selling prices (ASPs) for the Signatera minimal residual disease (MRD) test reached approximately $1,250, supported by expanded reimbursement coverage and improved payer alignment, with management reiterating its long-term ASP target of $2,000 per test.
• Operational scale and margin dynamics: The extraordinary volume surge late in the quarter led to higher-than-usual work-in-process inventory, temporarily weighing on gross margins but expected to normalize in subsequent quarters as cost recognition aligns with revenue.
• Clinical evidence and partnerships: Published studies and trial data, including the ALPHA3 and INVIGOR011 trials, reinforced Signatera’s clinical utility in enabling surgery avoidance and optimizing therapy timing, while integration with OncoEMR and the Foresight Diagnostics acquisition further differentiated Natera’s technology and commercial reach.

Drivers of Future Performance

Management expects future performance to be driven by continued volume growth, product innovation, and international expansion, while monitoring margin improvement and reimbursement trends.

• Japan launch and global expansion: The planned regulatory approval and commercial launch of Signatera in Japan could double the annual colorectal cancer testing market for Natera, leveraging established clinical guidelines and a single-payer system to facilitate rapid adoption.
• Advancements in early detection: Progress on the FIND colorectal cancer screening trial remains ahead of schedule, with management targeting a 2027 FDA submission. The company is also investing in a broader early detection platform and multi-cancer assay development, which could provide a new source of long-term growth.
• Reimbursement and pricing improvements: Ongoing efforts to secure Medicare coverage for additional cancer indications and gradual compliance by commercial payers in biomarker states are cited as key drivers for rising ASPs and margin expansion, though management acknowledges that further regulatory or payer shifts could impact these trends.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be monitoring (1) the pace and magnitude of Signatera’s launch and adoption in Japan, (2) interim and final data readouts from the FIND colorectal cancer early detection trial, and (3) progress on reimbursement expansion for additional cancer indications and improvements in average selling prices. Execution in these areas will be critical markers for sustained growth and profitability.

Natera currently trades at $216.20, down from $219.82 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.